

PROVINCIAL FUNDING SUMMARY

Crizotinib (Xalkori) for Advanced Non-Small Cell Lung Cancer

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please [see pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: May 17, 2013

This information is current as of May 26, 2014. The use of this document is directed by [pCODR's Terms of Use](#).

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Mar 1, 2014	Advanced non-small cell lung cancer with laboratory confirmed anaplastic lymphoma kinase-positive tumour as second line monotherapy for disease progression after prior platinum-based therapy for patients with ECOG 0-2. A BC Cancer Agency Compassionate Access Program request must be approved
AB	Funded	Oct 31, 2013	As a second line monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) in patients who have prior first line therapy.
SK	Funded	Oct 3, 2013	Second line treatment of patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) with an ECOG performance status <2 who have received one prior chemotherapy regimen
MB	Funded	Oct 17, 2013	For second-line therapy for patients with ALK-positive advanced NSCLC with ECOG ≤ 2.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	Oct 1, 2013	<p>For the treatment of ALK (anaplastic lymphoma kinase)-positive advanced NSCLC according to the following criteria:</p> <p>Initial criteria: For second-line therapy in patients with ALK-positive advanced non-small cell lung cancer (NSCLC) with ECOG performance status ≤ 2. Dosing: 250mg po bid Approval period: 1 year Exclusion: Patients who have not progressed during or following first-line therapy to treat advanced NSCLC are not eligible for approval</p> <p>Time limited funding: The Executive Officer has the discretion, as of October 1, 2013 to reimburse claims for Xalkori under the EAP for a time period specified by the Executive Officer for patients who have ALK-positive advanced non-small cell lung cancer (NSCLC) with ECOG performance status ≤ 2, and: (a) are currently receiving second-line treatment; (b) have recently relapsed on a second line treatment; or (c) have recently completed a second line treatment.</p> <p>Renewal criteria: Allowed as long as no disease progression stated by MD Approval period: 1 year</p>
NS	Funded	Dec 1, 2013	As a second-line therapy for patients with ALK-positive advanced non-small cell lung cancer with ECOG performance status ≤ 2 .
NB	Funded	Nov 8, 2013	Second-line therapy for patients with anaplastic lymphoma kinase (ALK) -positive advanced non-small cell lung cancer (NSCLC) with an ECOG performance status of 0-2.
NL	Funded	April 1, 2014	<p>Second-line therapy for patients with ALK-positive advanced non-small cell lung cancer (NSCLC) with ECOG performance status ≤ 2. Approval Period: 4 months Recommended Dose: 250mg twice daily until disease progression or development of unacceptable toxicity requiring discontinuation of crizotinib</p> <p>Renewals will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of crizotinib.</p>

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
PEI	Funded	Apr 8, 2014	For use as second-line therapy for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC) with ECOG performance status ≤ 2